Full Archive

Did we learn anything?

This recent round of earnings has been particularly revealing yet we wonder is anyone really paying attention. We wonder this often as for reasons unbeknownst to us investors and analysts seem immune to learning. That they focus so heavily on the numbers they forget how those numbers come about and who ultimately is responsible for making them happen. That in the end talent wins and talent at least in the...

Up vs Down

Just to quickly summarize the difference between what Tandem announced yesterday and what Insulet announced this afternoon you only need to read this one line from the earnings release “For the year ending December 31, 2022, the Company is raising its revenue growth guidance range to 14% to 17% (previously 12% to 16%).” Apparently, the headwinds faced by Tandem are not making their way to the east coast. We’re not trying to...

Diabesity Wins

fWe’re not sure who coined the phrase diabesity, but it appropriately describes what Lilly and Novo Nordisk have become. These two legacy companies are no longer in the business of diabetes alone and are now as equally focused on obesity therefore they are diabesity companies. Yes, as we noted in a previous post not that long ago the fight against fat is fattening the bottom lines of Novo and Lilly. Look...

Fast reaction

It didn’t take long for the street to react to Tandem’s results when they DECREASED full year sales guidance lowering it from $850 million to $865 million to $835 million to $845 million. During the call the company cited three factors that contributed to the reduction in guidance. 1. COVID/Staffing issues in endocrinologists offices 2. Competition 3. Inflation While issues 1 and 3 will change competition will not and one has to wonder whether...

This is a joke

“The need for affordable insulin is urgent, especially for uninsured populations,” said Heather Cianfrocco, CEO of Optum Rx, in a statement. “By working with Sanofi, we will improve access and lower costs for people who need this life-saving medication.” This statement comes from an article posted on Fierce Healthcare about the alliance between Sanofi and Optum to offer a 30-day supply of insulin for $35. This just the latest in a...

Way wacky

Not sure when we started calling this the wacky world of diabetes, but the phrase is very appropriate and continues to be proven each day. Today’s wacky items include 1. Dexcom shares recover from sell off. 2. Insulet announces full market release of Omnipod 5. 3. Tandem, Lilly, Novo Nordisk and Insulet all report this week. As we write shares of Dexcom are up nearly 4% which we anticipated. The company reported results last...

Simple Math

After some raucous after-hours trading shares of Dexcom at the moment are down a rather muted 6%. As we noted yesterday this was expected and, in our opinion, creates a buying opportunity. For all the pontificating when it comes to CGM the math is quite simple and we see Dexcom having a major advantage. Here’s why. The Control IQ from Tandem and the Omnipod 5 from Insulet both work with the...